1
|
Hakobyan V, Sargsyan K, Elbakyan H, Sargsyan V, Markosyan T, Chobanyan G, Badalyan M, Kharatyan S. Duration of Immunity in Cattle to Lumpy Skin Disease Utilizing a Sheep Pox Vaccine. Vet Sci 2024; 11:164. [PMID: 38668431 PMCID: PMC11053425 DOI: 10.3390/vetsci11040164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 04/01/2024] [Accepted: 04/03/2024] [Indexed: 04/29/2024] Open
Abstract
The transmission of lumpy skin disease (LSD) occurs through ticks, mosquitoes, and flies. The most effective way to combat LSD is to conduct large-scale vaccination, covering the entire cattle population with safe and effective vaccines, while introducing restrictions on the movement of livestock. The first and only LSD cases that occurred in Armenia happened in 2015,and they were controlled with the use of a once yearly heterologous sheep pox vaccine for cattle in high-risk areas. We have previously reported on the safety and immunogenicity of this vaccine in cattle, but information on the duration of immunity is lacking. Our aim was to determine the duration of immunity to the LSD virus (LSDV) in cattle when utilizing a heterologous sheep pox vaccine. We have evaluated antibodies in cattle blood prior to and post-vaccination (1, 6, and 11 months). We have utilized an enzyme-linked immunosorbent assay to follow the development and waning of LSDV antibodies in vaccinated cattle in two age groups: 1) young unvaccinated cattle ≤12 months of age and 2) adult cattle that had previously been vaccinated. Our results were consistent with our previous study in Armenia, showing a high level of population immunity, 80.0-83.3%, in both age groups at 1 month, with a significant (p = 0.001) drop for young cattle at 6 months. Previously vaccinated adult cattle showed a longer duration of immunity at 11 months for this heterologous sheep pox vaccine. Based on these data, we advise that young cattle receive an additional booster vaccination 4-6 months after their first vaccination, and then yearly vaccinations in high-risk areas.
Collapse
Affiliation(s)
- Varduhi Hakobyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Khachik Sargsyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Hasmik Elbakyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Vazgen Sargsyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Tigran Markosyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Gayane Chobanyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| | - Manvel Badalyan
- Chair of Biosciences and General Chemistry, Armenian National Agrarian University, 74 Teryan Street, Yerevan 0009, Armenia;
| | - Satenik Kharatyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Shengavit, Yerevan 0071, Armenia; (K.S.); (H.E.); (V.S.); (T.M.); (G.C.); (S.K.)
| |
Collapse
|
2
|
Kumwichar P, Poonsiri C, Botwright S, Sirichumroonwit N, Loharjun B, Thawillarp S, Cheewaruangroj N, Chokchaisiripakdee A, Teerawattananon Y, Chongsuvivatwong V. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data. JMIR Public Health Surveill 2024; 10:e48255. [PMID: 38441923 PMCID: PMC10951833 DOI: 10.2196/48255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 10/31/2023] [Accepted: 02/08/2024] [Indexed: 03/07/2024] Open
Abstract
BACKGROUND The durability of heterologous COVID-19 vaccine effectiveness (VE) has been primarily studied in high-income countries, while evaluation of heterologous vaccine policies in low- and middle-income countries remains limited. OBJECTIVE We aimed to evaluate the duration during which the VE of heterologous COVID-19 vaccine regimens in mitigating serious outcomes, specifically severe COVID-19 and death following hospitalization with COVID-19, remains over 50%. METHODS We formed a dynamic cohort by linking records of Thai citizens aged ≥18 years from citizen vital, COVID-19 vaccine, and COVID-19 cases registry databases between May 2021 and July 2022. Encrypted citizen identification numbers were used to merge the data between the databases. This study focuses on 8 common heterologous vaccine sequences: CoronaVac/ChAdOx1, ChAdOx1/BNT162b2, CoronaVac/CoronaVac/ChAdOx1, CoronaVac/ChAdOx1/ChAdOx1, CoronaVac/ChAdOx1/BNT162b2, BBIBP-CorV/BBIBP-CorV/BNT162b2, ChAdOx1/ChAdOx1/BNT162b2, and ChAdOx1/ChAdOx1/mRNA-1273. Nonimmunized individuals were considered for comparisons. The cohort was stratified according to the vaccination status, age, sex, province location, month of vaccination, and outcome. Data analysis employed logistic regression to determine the VE, accounting for potential confounders and durability over time, with data observed over a follow-up period of 7 months. RESULTS This study includes 52,580,841 individuals, with approximately 17,907,215 and 17,190,975 receiving 2- and 3-dose common heterologous vaccines (not mutually exclusive), respectively. The 2-dose heterologous vaccinations offered approximately 50% VE against severe COVID-19 and death following hospitalization with COVID-19 for 2 months; however, the protection significantly declined over time. The 3-dose heterologous vaccinations sustained over 50% VE against both outcomes for at least 8 months, as determined by logistic regression with durability time-interaction modeling. The vaccine sequence consisting of CoronaVac/CoronaVac/ChAdOx1 demonstrated >80% VE against both outcomes, with no evidence of VE waning. The final monthly measured VE of CoronaVac/CoronaVac/ChAdOx1 against severe COVID-19 and death following hospitalization at 7 months after the last dose was 82% (95% CI 80.3%-84%) and 86.3% (95% CI 83.6%-84%), respectively. CONCLUSIONS In Thailand, within a 7-month observation period, the 2-dose regimens could not maintain a 50% VE against severe and fatal COVID-19 for over 2 months, but all of the 3-dose regimens did. The CoronaVac/CoronaVac/ChAdOx1 regimen showed the best protective effect against severe and fatal COVID-19. The estimated durability of 50% VE for at least 8 months across all 3-dose heterologous COVID-19 vaccine regimens supports the adoption of heterologous prime-boost vaccination strategies, with a primary series of inactivated virus vaccine and boosting with either a viral vector or an mRNA vaccine, to prevent similar pandemics in low- and middle-income countries.
Collapse
Affiliation(s)
- Ponlagrit Kumwichar
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Chittawan Poonsiri
- Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand
| | - Siobhan Botwright
- Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand
| | - Natchalaikorn Sirichumroonwit
- Department of Medical Services, Institute of Medical Research and Technology Assessment, Ministry of Public Health, Nonthaburi, Thailand
| | - Bootsakorn Loharjun
- Department of Medical Services, Institute of Medical Research and Technology Assessment, Ministry of Public Health, Nonthaburi, Thailand
| | | | | | | | - Yot Teerawattananon
- Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand
| | | |
Collapse
|
3
|
Vijayan A, Sukumaran A, Jones S, Paul A, Ahmed S, Mehta P, Mohanan M, Kumar S, Easwaran S, Shenoy P. Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines. Cureus 2024; 16:e55764. [PMID: 38586774 PMCID: PMC10998979 DOI: 10.7759/cureus.55764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2024] [Indexed: 04/09/2024] Open
Abstract
BACKGROUND An additional dose of COVID-19 vaccine is being offered to vaccinated people, especially those immunocompromised. The most widely available vaccines in India are the adenoviral vector-based AZD1222 (ChAdOx1 nCoV-19) and the heat-inactivated (BBV152). This study investigated the efficacy of both vaccines in patients with autoimmune rheumatic diseases (AIRD). OBJECTIVES To compare final anti-SARS-CoV-2 antibody titers, neutralization of pseudovirions by these antibodies, and T cell responses between patients of AIRD who had received the third dose of AZD1222 and BBV152 vaccines. METHODS Patients with stable AIRD who had completed two doses of COVID-19 vaccination but had a suboptimal response (anti-receptor binding domain (RBD) antibody<212) were randomized (1:1) to receive either AZD1222 or BBV152 as a booster dose. Patients with previous hybrid immunity or those who developed COVID-19 during the trial were excluded. Antibody titers, neutralization of Wuhan and Omicron pseudovirions, and interferon release by T cells (enzyme-linked immunosorbent spot (ELISpot)) in response to the Spike antigen were measured four weeks after this booster dose. RESULTS 146 were screened, 91 were randomized, and 67 were analyzed per protocol. The third dose improved antibody titers (p<0.001), neutralization of the Wuhan strain (p<0.001), and T cell interferon release (p<0.001) but not neutralization of the Omicron strain (p=0.24). Antibody titers were higher (p<0.005) after ADZ1222 boost (2,414 IU (interquartile range (IQR): 330-10,315)) than BBV1222 (347.7 IU (0.4-973)). Neutralization of the Wuhan stain was better (AZD1222: 76.6%(23.0-95.45) versus BBV152 (32.7% (0-78.9), p=0.03 by ANCOVA). Neutralization of Omicron (0 (0-28.4) vs 0 (0-4.8)) and T cell interferon release (57.0 IU (23.5-95) vs 50.5 IU (13.2-139)) were similar. CONCLUSION The third dose improved all parameters of immunogenicity in AIRD patients with previous inadequate responses except Omicron neutralization. The vector-based vaccine exhibits notable efficacy, particularly in antibody titers and neutralizing the Wuhan strain. TRIAL REGISTRATION CTRI/2021/12/038928.
Collapse
Affiliation(s)
- Anuroopa Vijayan
- Rheumatology, Dr Shenoys CARE, Kochi, IND
- Rheumatology, Sree Sudheendra Medical Mission, Kochi, IND
| | | | - Sara Jones
- Pathogen Biology, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IND
| | - Aby Paul
- Pharmacy, Dr Shenoys CARE, Kochi, IND
| | - Sakir Ahmed
- Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND
| | - Pankti Mehta
- Clinical Immunology and Rheumatology, King George's Medical University, Lucknow, IND
| | | | - Santhosh Kumar
- Cancer Biology, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, IND
| | | | | |
Collapse
|
4
|
Barouch SE, Chicz TM, Blanc R, Barbati DR, Parker LJ, Tong X, McNamara RP. Concurrent administration of COVID-19 and influenza vaccines enhances Spike-specific antibody responses. bioRxiv 2023:2023.09.12.557347. [PMID: 37745590 PMCID: PMC10515870 DOI: 10.1101/2023.09.12.557347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
The bivalent COVID-19 mRNA boosters became available in fall 2022 and were recommended alongside the seasonal influenza vaccine. However, the immunogenicity of concurrent versus separate administration of these vaccines remains unclear. Here, we analyzed antibody responses in healthcare workers who received the bivalent COVID-19 booster and the influenza vaccine on the same day or different days. IgG1 responses to SARS-CoV-2 Spike were higher at peak immunogenicity and 6 months following concurrent administration compared with separate administration of the COVID-19 and influenza vaccines. These data suggest that concurrent administration of these vaccines may yield higher and more durable SARS-CoV-2 antibody responses.
Collapse
Affiliation(s)
| | | | - Ross Blanc
- Ragon Institute of MGH, MIT, and Harvard
| | | | | | - Xin Tong
- Ragon Institute of MGH, MIT, and Harvard
| | | |
Collapse
|
5
|
Szekely J, Swangphon P, Nanakorn N, Chaimuti P, Nualnoi T, Wongwitwichot P, Somapa N, Somapa D, Pengsakul T. Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage. Vaccines (Basel) 2023; 11:1230. [PMID: 37515045 PMCID: PMC10383937 DOI: 10.3390/vaccines11071230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/05/2023] [Accepted: 07/09/2023] [Indexed: 07/30/2023] Open
Abstract
This study aims to analyze the neutralization ability against Omicron parental variants in five clusters of individuals with different Coronavirus disease (COVID-19) immunity backgrounds, including individuals receiving a homologous or heterologous vaccine without prior infection, recovered patients with homologous or heterologous vaccination, and recovery patients without vaccination. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surrogate virus neutralization assay was performed on serum samples. Spearman correlation analysis showed that the percent inhibition against Omicron B.1.1.529 and BA.2 was significantly related to the period of serum collection (r = 0.730 and 0.787, p < 0.001, respectively). Very strong correlation between percent inhibition of neutralizing antibody against Omicron B.1.1.529 and BA.2 variants (rs = 0.973, p < 0.001) was also observed. The neutralizing activity of the sera from recovery patients receiving homologous and heterologous vaccine against the wild-type, B.1.1.529, and BA.2 Omicron variants was significantly higher (p < 0.001) than that of recovery patients without vaccination. This study robustly showed that the breakthrough SARS-CoV-2 Omicron variant in individuals who received homologous and heterologous vaccines had a high level of neutralizing activity against B.1.1.529 and BA.2 parental lineage of XBB subvariants. Therefore, the next-generation COVID-19 vaccine against emerging variants is needed to improve resilience against ongoing variants, particularly for persons who have never been infected.
Collapse
Affiliation(s)
- Jidapa Szekely
- Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand
| | - Piyawut Swangphon
- Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand
| | - Natthaphon Nanakorn
- Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand
| | - Panuttha Chaimuti
- Immunology and Virology Unit, Department of Medical Technology and Clinical Pathology, Hat Yai Hospital, Hat Yai 90110, Thailand
| | - Teerapat Nualnoi
- Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand
| | - Paweena Wongwitwichot
- Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand
| | - Namchoke Somapa
- Master Labs Incorporation Co., Ltd., Bangkok 10510, Thailand
| | - Denpong Somapa
- Master Labs Incorporation Co., Ltd., Bangkok 10510, Thailand
| | - Theerakamol Pengsakul
- Faculty of Environmental Management, Prince of Songkla University, Hat Yai 90110, Thailand
- Health and Environmental Research Center, Faculty of Environmental Management, Prince of Songkla University, Hat Yai 90110, Thailand
| |
Collapse
|
6
|
Hakobyan V, Sargsyan K, Kharatyan S, Elbakyan H, Sargsyan V, Markosyan T, Vardanyan T, Badalyan M, Achenbach JE. The Serological Response in Cattle following Administration of a Heterologous Sheep Pox Virus Strain Vaccine for Protection from Lumpy Skin Disease; Current Situation in Armenia. Vet Sci 2023; 10:vetsci10020102. [PMID: 36851406 PMCID: PMC9965929 DOI: 10.3390/vetsci10020102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 01/29/2023] [Accepted: 01/29/2023] [Indexed: 02/05/2023] Open
Abstract
Lumpy skin disease (LSD) is a highly infectious viral disease of cattle caused by LSD virus (LSDV), which was first reported in Armenia in late 2015. It was identified in pasture-raised cattle near the border with Iran. Currently, vaccination plays a key role in preventing further incursion of disease in high-risk areas. The purpose of this work was to assess the quality of vaccination currently used in Armenia by determining the immune response of the heterologous dry culture sheep pox virus-based vaccine against LSD in cattle. Seroprevalence and seroconversion testing was carried out using an ELISA to detect specific antibodies against LSD before and 30 days after vaccination in three adjacent regions of Armenia (Ararat, Armavir, Gegharkunik). Ixodes ticks were also examined for the presence of LSDV via real-time PCR. We found that the heterologous vaccine used in Armenia creates a high level of population immunity of 86.09% (83.83-87.97%) and no adverse side effects were observed in cattle. Of the 6 types of Ixodes ticks identified and tested, we found no evidence of LSDV circulating in these vectors. These results suggest that regular serological monitoring via ELISA and heterologous vaccination should continue in areas of Armenia at high risk for incursion of LSD to reduce the spread of this highly infectious transboundary disease.
Collapse
Affiliation(s)
- Varduhi Hakobyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
- Correspondence: ; Tel.: +374-91453912
| | - Khachik Sargsyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Satenik Kharatyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Hasmik Elbakyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Vazgen Sargsyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Tigran Markosyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Tigranuhi Vardanyan
- Scientific Center for Risk Assessment and Analysis in Food Safety Area, 107/2 Masis Highway, Yerevan 0071, Armenia
| | - Manvel Badalyan
- General Biology Department, Armenian National Agrarian University, 74 Teryan Street, Yerevan 0009, Armenia
| | - Jenna E. Achenbach
- Battelle Memorial Institute, 1001 Research Park Boulevard, Town Center Two, Suite 400, Charlottesville, VA 22911, USA
| |
Collapse
|
7
|
Chandrasekar SS, Kingstad-Bakke BA, Wu CW, Phanse Y, Osorio JE, Talaat AM. A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens. Vaccines (Basel) 2023; 11. [PMID: 36851180 DOI: 10.3390/vaccines11020302] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 12/28/2022] [Accepted: 01/25/2023] [Indexed: 02/03/2023] Open
Abstract
Infectious bronchitis (IB) is an acute respiratory disease of chickens caused by the avian coronavirus Infectious Bronchitis Virus (IBV). Modified Live Virus (MLV) vaccines used commercially can revert to virulence in the field, recombine with circulating serotypes, and cause tissue damage in vaccinated birds. Previously, we showed that a mucosal adjuvant system, QuilA-loaded Chitosan (QAC) nanoparticles encapsulating plasmid vaccine encoding for IBV nucleocapsid (N), is protective against IBV. Herein, we report a heterologous vaccination strategy against IBV, where QAC-encapsulated plasmid immunization is followed by Modified Vaccinia Ankara (MVA) immunization, both expressing the same IBV-N antigen. This strategy led to the initiation of robust T-cell responses. Birds immunized with the heterologous vaccine strategy had reduced clinical severity and >two-fold reduction in viral burden in lachrymal fluid and tracheal swabs post-challenge compared to priming and boosting with the MVA-vectored vaccine alone. The outcomes of this study indicate that the heterologous vaccine platform is more immunogenic and protective than a homologous MVA prime/boost vaccination strategy.
Collapse
|
8
|
Bulatov YA, Sametova ZZ, Turyskeldi SS, Amanova ZT, Shoraeva KA, Kondibaeva ZB, Abitaev RT, Ussembay AK. Biochemical Analysis of the Blood of Cattle after Vaccination with a Heterologous Vaccine for Lumpy Skin Disease. Bull Exp Biol Med 2023; 174:346-348. [PMID: 36723742 DOI: 10.1007/s10517-023-05706-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Indexed: 02/02/2023]
Abstract
We studied the biochemical parameters of the blood of cattle after immunization against lumpy skin disease with a vaccine made from an attenuated heterologous goat pox virus (strain G20-LKV). Blood samples were obtained from animals on days 7, 14, and 21 after vaccination. The vaccine did not affect biochemical parameters of the blood. A slight increase in total protein and AST on day 14 indicates the expected reactions to the stimulation of the immune system after vaccination. The levels of direct and total bilirubin, ALT, urea, glucose, cholesterol, and creatinine in vaccinated animals remained within the physiological limits.
Collapse
Affiliation(s)
- Ye A Bulatov
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan.
| | - Zh Zh Sametova
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - Sh S Turyskeldi
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - Zh T Amanova
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - K A Shoraeva
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - Zh B Kondibaeva
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - R T Abitaev
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| | - A K Ussembay
- Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Guardeiskiy, Republic of Kazakhstan
| |
Collapse
|
9
|
Díaz-Alberola I, Espuch-Oliver A, García-Aznar JM, Ganoza-Gallardo C, Aguilera-Franco M, Sampedro A, Jiménez P, López-Nevot MÁ. Common Variable Immunodeficiency Associated with a De Novo IKZF1 Variant and a Low Humoral Immune Response to the SARS-CoV-2 Vaccine. J Clin Med 2022; 11:2303. [PMID: 35566429 PMCID: PMC9101713 DOI: 10.3390/jcm11092303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/15/2022] [Accepted: 04/18/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND AND AIMS Common variable immunodeficiency (CVID) comprises a group of diseases with heterogeneous clinical and immunological manifestations. Several mutations have been identified in genes encoding proteins essential for immune function. Our aim was to phenotypically and genotypically characterize a patient diagnosed with CVID and study his response to the SARS-CoV-2 vaccine. METHODS We performed a next-generation sequencing analysis, a CMIA, and an ELISA to analyze the humoral and cellular response to the SARS-CoV-2 vaccine, respectively. We also employed flow cytometry and immunoturbidimetry to assess the patient's global immune status. RESULTS We found a low humoral but positive cellular response to the SARS-CoV-2 vaccine. NGS screening revealed a transition from guanine to adenine at position c.485 of the IKZF1 gene in heterozygosity, giving rise to the R162Q variant, which was not present in his parents. CONCLUSIONS The R162Q variant of the IKZF1 gene has been associated with CVID type 13, but always with an autosomal dominant inheritance with high penetrance. Therefore, we present for the first time a case of CVID associated with a de novo heterozygous R162Q variant in the IKZF1 gene in a patient with a low humoral immune response to the complete COVID-19 vaccination program.
Collapse
Affiliation(s)
- Irene Díaz-Alberola
- Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; (P.J.); (M.Á.L.-N.)
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
- Programa de Doctorado en Biomedicina, Universidad de Granada, 18016 Granada, Spain
| | - Andrea Espuch-Oliver
- Hospital General Nuestra Señora del Prado, Talavera de la Reina, 45600 Toledo, Spain;
| | | | | | - María Aguilera-Franco
- Servicio de Microbiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; (M.A.-F.); (A.S.)
| | - Antonio Sampedro
- Servicio de Microbiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; (M.A.-F.); (A.S.)
| | - Pilar Jiménez
- Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; (P.J.); (M.Á.L.-N.)
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
| | - Miguel Ángel López-Nevot
- Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; (P.J.); (M.Á.L.-N.)
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
- Departamento de Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, 18016 Granada, Spain
| |
Collapse
|
10
|
Lee MH, Kim BJ. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol 2022; 60:321-34. [PMID: 35157221 DOI: 10.1007/s12275-022-1621-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/30/2021] [Accepted: 12/31/2021] [Indexed: 12/11/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.
Collapse
|
11
|
Saltykov YV, Kolosova AA, Filonova NN, Chichkin AN, Feodorova VA. Genetic Evidence of Multiple Introductions of Lumpy Skin Disease Virus into Saratov Region, Russia. Pathogens 2021; 10:716. [PMID: 34200428 DOI: 10.3390/pathogens10060716] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 06/03/2021] [Accepted: 06/04/2021] [Indexed: 12/03/2022] Open
Abstract
Lumpy skin disease virus (LSDV) is the causative agent of lumpy skin disease (LSD) that has been recently reported in the South-East and North Asian parts of the Russian Federation. During 2017–2019, there were more than 30 LSD outbreaks in Saratov Region despite active inoculation of cattle with heterologous vaccine. Importantly, the first case of the novel recombinant LSDV strain was reported here in 2017. This study aimed to determine the main clonal lineage(s) of LSDV strains circulated within Saratov Region and other regions of Russia since the first introduction of LSDV. The molecular typing and subtyping based on the coding regions of the G-protein-coupled chemokine receptor (GPCR) gene resulted in a discrimination of all outbreak-related LSDV strains into two main types, such as Type I and Type II, and subtypes Ia-d and IIa-g. Phylogenetically, eleven LSDV lineages were revealed in Russia including the five ones in Saratov Region. They were the following: (i) the Neethling wild Type Ia/2017; (ii) the recombinant Saratov IIc/2017/2019; (iii) the specific Dergachevskyi IId/2017; (iv) the Khvalynsky IIg/2018, and (v) the Haden-Type IIa lineage for the six LSDV strains detected in cattle immunized with heterologous vaccine during the last LSD outbreak in the Saratov Region, Nesterovo Village, in 2019 (Nesterovo-2019 strains). A single LSDV strain detected in Saratov Region in 2017 had the same Type Ia that was identified in 2016 in the bordered Republic of Kazakhstan. Phylogeographic analysis demonstrated three nominal clusters of LSDV types in the following Russian Federation territories: (I) the Central European part; (II) the South-East of the European part; (III) the North Asian part. Cluster I was represented by mainly Type I strains, while both Clusters 2 and 3 contained predominantly Type II strains. The Clusters I and II partially overlapped, while Cluster 3 was separate. Multiple introductions of LSDV into Saratov Region in 2017–2019 using GPCR-based molecular typing and subtyping were revealed. This scheme is a promising tool for molecular discrimination of LSDV strains derived from both vaccinated and unvaccinated against LSD cattle as well as for molecular epidemiology.
Collapse
|
12
|
Chandrasekar SS, Phanse Y, Hildebrand RE, Hanafy M, Wu CW, Hansen CH, Osorio JE, Suresh M, Talaat AM. Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization. Vaccines (Basel) 2021; 9:132. [PMID: 33562141 PMCID: PMC7914464 DOI: 10.3390/vaccines9020132] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 01/31/2021] [Accepted: 02/02/2021] [Indexed: 12/11/2022] Open
Abstract
The rapid transmission of SARS-CoV-2 in the USA and worldwide necessitates the development of multiple vaccines to combat the COVID-19 global pandemic. Previously, we showed that a particulate adjuvant system, quil-A-loaded chitosan (QAC) nanoparticles, can elicit robust immunity combined with plasmid vaccines when used against avian coronavirus. Here, we report on the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens. Only the heterologous intranasal immunization strategy elicited neutralizing antibodies against SARS-CoV-2 in serum and bronchoalveolar lavage of mice, suggesting a protective vaccine. The same prime/boost strategy led to the induction of type 1 and type 17 T-cell responses and polyfunctional T-cells expressing multiple type 1 cytokines (e.g., IFN-γ, TNFα, IL-2) in the lungs and spleens of vaccinated mice. In contrast, the plasmid homologous vaccine strategy led to the induction of local mono and polyfunctional T-cells secreting IFN-γ. Outcomes of this study support the potential of QAC-nano vaccines to elicit significant mucosal immune responses against respiratory coronaviruses.
Collapse
Affiliation(s)
- Shaswath S. Chandrasekar
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
| | | | - Rachel E. Hildebrand
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
| | - Mostafa Hanafy
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
- Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt
| | - Chia-Wei Wu
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
| | - Chungyi H. Hansen
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
| | - Jorge E. Osorio
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
- Colombia Wisconsin One Health Consortium, Universidad Nacional Medellín, Calle 75#79a 5, Colombia
| | - M. Suresh
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
| | - Adel M. Talaat
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; (S.S.C.); (R.E.H.); (M.H.); (C.-W.W.); (C.H.H.); (J.E.O.); (M.S.)
- Pan Genome Systems, Madison, WI 53719, USA;
| |
Collapse
|
13
|
Talat S, Abouelmaatti RR, Almeer R, Abdel-Daim MM, Elfeil WK. Comparison of the Effectiveness of Two Different Vaccination Regimes for Avian Influenza H9N2 in Broiler Chicken. Animals (Basel) 2020; 10:E1875. [PMID: 33066560 DOI: 10.3390/ani10101875] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2020] [Revised: 10/08/2020] [Accepted: 10/09/2020] [Indexed: 12/16/2022] Open
Abstract
Low pathogenic avian influenza virus is one of the major threats that has been affecting the poultry industry in the Middle East region for decades. Attempts to eradicate this disease have failed. Currently, there are commercial vaccines that are either imported or produced locally from recently circulating isolates of H9N2 in Egypt and Middle Eastern countries. This present work focused on comparing the effectiveness of two vaccines belonging to these categories in Egypt. Two commercial broiler flocks (Cobb-500 Broiler) with maternally derived immunity (MDA) against H9N2 virus were employed and placed under normal commercial field conditions or laboratory conditions. Immunity was evaluated on the basis of detectable humoral antibodies against influenza H9N2 virus, and challenge was conducted at 28 days of life using a recent wild H9N2 virus. The results showed that vaccination on the 7th day of life provided significantly higher immune response in both vaccine types, with significantly lower virus shedding compared to vaccination at day 1 of life, regardless of field or laboratory conditions. In addition, the vaccine produced from a recent local H9N2 isolate (MEFLUVAC-H9-16) provided a significantly higher humoral immune response under both field and laboratory conditions, as measured by serology and virus shedding (number of shedders and amount of shedding virus), being significantly lower following challenge on the 28th day of life, contrary to the imported H9 vaccine. In conclusion, use of H9N2 vaccine at 7 days of life provided a significantly higher protection than vaccination at day 1 of life in birds with MDA, suggesting vaccination regimes between 5-8-days of life for broiler chicks with MDA. Moreover, use of a vaccine prepared from a recently circulating H9N2 virus showed significantly higher protection and was more suitable for birds in the Middle East.
Collapse
|
14
|
Jia Q, Horwitz MA. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis. Front Cell Infect Microbiol 2018; 8:154. [PMID: 29868510 PMCID: PMC5963219 DOI: 10.3389/fcimb.2018.00154] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 04/24/2018] [Indexed: 12/11/2022] Open
Abstract
Francisella tularensis is the causative agent of tularemia and a Tier I bioterrorism agent. In the 1900s, several vaccines were developed against tularemia including the killed "Foshay" vaccine, subunit vaccines comprising F. tularensis protein(s) or lipoproteins(s) in an adjuvant formulation, and the F. tularensis Live Vaccine Strain (LVS); none were licensed in the U.S.A. or European Union. The LVS vaccine retains toxicity in humans and animals-especially mice-but has demonstrated efficacy in humans, and thus serves as the current gold standard for vaccine efficacy studies. The U.S.A. 2001 anthrax bioterrorism attack spawned renewed interest in vaccines against potential biowarfare agents including F. tularensis. Since live attenuated-but not killed or subunit-vaccines have shown promising efficacy and since vaccine efficacy against respiratory challenge with less virulent subspecies holarctica or F. novicida, or against non-respiratory challenge with virulent subsp. tularensis (Type A) does not reliably predict vaccine efficacy against respiratory challenge with virulent subsp. tularensis, the route of transmission and species of greatest concern in a bioterrorist attack, in this review, we focus on live attenuated tularemia vaccine candidates tested against respiratory challenge with virulent Type A strains, including homologous vaccines derived from mutants of subsp. holarctica, F. novicida, and subsp. tularensis, and heterologous vaccines developed using viral or bacterial vectors to express F. tularensis immunoprotective antigens. We compare the virulence and efficacy of these vaccine candidates with that of LVS and discuss factors that can significantly impact the development and evaluation of live attenuated tularemia vaccines. Several vaccines meet what we would consider the minimum criteria for vaccines to go forward into clinical development-safety greater than LVS and efficacy at least as great as LVS, and of these, several meet the higher standard of having efficacy ≥LVS in the demanding mouse model of tularemia. These latter include LVS with deletions in purMCD, sodBFt , capB or wzy; LVS ΔcapB that also overexpresses Type VI Secretion System (T6SS) proteins; FSC200 with a deletion in clpB; the single deletional purMCD mutant of F. tularensis SCHU S4, and a heterologous prime-boost vaccine comprising LVS ΔcapB and Listeria monocytogenes expressing T6SS proteins.
Collapse
Affiliation(s)
- Qingmei Jia
- Division of Infectious Diseases, Department of Medicine, 37-121 Center for Health Sciences, School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
| | - Marcus A. Horwitz
- Division of Infectious Diseases, Department of Medicine, 37-121 Center for Health Sciences, School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
| |
Collapse
|
15
|
Abstract
BACKGROUND In 1997, highly pathogenic avian influenza (HPAI) viruses caused outbreaks of disease in domestic poultry markets in Hong Kong. The virus has also been detected in infected poultry in Europe and Africa. OBJECTIVE The objective of this study was to determine the efficacy of a heterologous vaccine administered with and without the aluminum hydroxide adjuvant in ferrets challenged with HPAI (A/Vietnam/1203/04). METHODS Animals in four of the five groups were vaccinated twice 21 days apart, with two doses of a heterologous monovalent subvirion vaccine with or without an aluminum hydroxide adjuvant and challenged with a lethal target dose of A/Vietnam/1203/04. RESULTS All animals vaccinated with the heterologous vaccine in combination with the aluminum hydroxide adjuvant survived a lethal challenge of A/Vietnam/1203/04. Four of the eight animals vaccinated with 30 μg of the vaccine without the adjuvant survived, while two of the eight animals vaccinated with 15 μg of the vaccine without the adjuvant survived. None of the unvaccinated control animals survived challenge. Additionally, changes in virus recovered from nasal washes and post-mortem tissues and serology suggest vaccine efficacy. CONCLUSIONS Altogether, the data suggest that the heterologous vaccine in combination with the aluminum hydroxide adjuvant offers maximum protection against challenge with A/Vietnam/1203/04 when compared to the unvaccinated control animals or animals vaccinated without any adjuvant.
Collapse
Affiliation(s)
- Eric M Vela
- Battelle, 505 King Avenue, Columbus, OH 43201, USA.
| | | | | | | | | |
Collapse
|